Radionetics

Radionetics Oncology is a clinical-stage biotechnology company focused on the discovery and development of novel radiopharmaceuticals for the treatment of a wide range of oncology indications. The company leverages a proprietary platform to identify and optimize small molecule radioligands that target G protein-coupled receptors (GPCRs), which are highly expressed in various solid tumors. By combining the precision of small molecule targeting with the potent cell-killing power of radioisotopes, Radionetics aims to create next-generation therapies with improved efficacy and safety profiles. The company's lead programs are currently advancing through early clinical trials, supported by a significant strategic partnership with Eli Lilly and Company.